GSA Capital Partners’s Immunovant IMVT Stock Holding History
Bought
Maintained
Sold
Other funds holding IMVT
GSA Capital Partners's IMVT Position: Q3 2026 in Review
GSA Capital Partners sold out of Immunovant (IMVT) in Q3 2026, closing a stake of 65,267 shares — an estimated $2.52M sold.
GSA Capital Partners first reported a position in IMVT in Q4 2020 and held it in 13 quarters. The position peaked at $2.52M in Q2 2026. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.
- GSA Capital Partners reported no remaining Immunovant position as of Q3 2026 after selling out during the quarter.
- GSA Capital Partners sold 65,267 Immunovant shares in Q3 2026, an estimated $2.52M.
- GSA Capital Partners first reported a position in Immunovant in Q4 2020 and held it in 13 quarters.
- GSA Capital Partners's Immunovant position peaked at $2.52M in Q2 2026.
- 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.